Redeye comments on Freemelt’s Q3 results, which were roughly in line with expectations in terms of s...
Redeye comments on the US CMS rate change for 2025.
Redeye provides an initial comment on the Q3 2024 report from Cheffelo, which came in below our esti...
Redeye states that the CoinShares Q3 2024 report was solid, with asset management fees above RRe, wh...
Redeye initiates coverage of Jumpgate, a gaming company focused on PC and Console.
Last year was a fairly weak one for Tallinna Sadam, but the tone has changed for 2024.
IRLAB’s Q324 results highlighted progress across its clinical pipeline.
Redeye comments on the proposed increased rate for Medicare and Medicaid for 2025 under the OPPS and...
Cyberattack impact on sales likely ~SEK 5-10m We cut '24e-'26e sales by 1% '25e-'26e EV/EBIT 21x-10x...
Redeye views today’s press release from Acarix as a positive development, confirming new reimburseme...
While the Q3’24 report did not contain any particular surprises in terms of financials, it did provi...
Redeye updates its estimates after reviewing Tessin's Q3 report, which came in below our expectation...
Redeye makes some revisions based on the Q3 report.
Ahead of Relais Q3 report, we maintain our estimates intact.
Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of B...
Raute’s Q3 earnings were already very strong, and although new order softness persists valuation als...
Etteplan’s Q3 was weak as was expected after the two profit warnings the company gave prior to the r...
Redeye comments on Tessin’s Q3 results, which were weaker than expected.
Redeye provides an update following CLS’s Q3 2024 report.
Føroya Banki reported a Q3 2024 net profit of DKK 96m, DKK 7m (8%) above our estimate.
